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Abstract 
Background: Heterologous production of natural products in Escherichia coli has emerged as an attractive strategy 
to obtain molecules of interest. Although technically feasible most of them are still constrained to laboratory scale 
production. Therefore, it is necessary to develop reasonable scale-up strategies for bioprocesses aiming at the over-
production of targeted natural products under industrial scale conditions. To this end, we used the production of the 
antibiotic valinomycin in E. coli as a model system for scalable bioprocess development based on consistent fed-batch 
cultivations.
Results: In this work, the glucose limited fed-batch strategy based on pure mineral salt medium was used through-
out all scales for valinomycin production. The optimal glucose feed rate was initially detected by the use of a bio-
catalytically controlled glucose release (EnBase® technology) in parallel cultivations in 24-well plates with continuous 
monitoring of pH and dissolved oxygen. These results were confirmed in shake flasks, where the accumulation of 
valinomycin was highest when the specific growth rate decreased below 0.1 h−1. This correlation was also observed 
for high cell density fed-batch cultivations in a lab-scale bioreactor. The bioreactor fermentation produced valinomy-
cin with titers of more than 2 mg L−1 based on the feeding of a concentrated glucose solution. Valinomycin produc-
tion was not affected by oscillating conditions (i.e. glucose and oxygen) in a scale-down two-compartment reactor, 
which could mimic similar situations in industrial bioreactors, suggesting that the process is very robust and a scaling 
of the process to a larger industrial scale appears a realistic scenario.
Conclusions: Valinomycin production was scaled up from mL volumes to 10 L with consistent use of the fed-batch 
technology. This work presents a robust and reliable approach for scalable bioprocess development and represents 
an example for the consistent development of a process for a heterologously expressed natural product towards the 
industrial scale.
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Background
Natural products are of great significance because they 
are important sources for pharmaceuticals to treat 
human and animal diseases [1]. These natural compounds 
include nonribosomal peptides (NRPs, e.g. vancomycin), 
polyketides (PKs, e.g. erythromycin) and their hybrids 
(NRP/PKs, e.g. epothilone). In recent years, a large num-
ber of NRPs and PKs have been discovered by genome 
mining [2], however, their potential further development 
and clinical application are often hampered due to the 
fact that their native producers are not cultivable. Alter-
natively, with the development of synthetic biology, some 
NRPs and PKs have been synthesized by heterologous 
expression of their biosynthetic gene clusters in several 
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well-characterized and genetically tractable host micro-
organisms [3–12]. While multiple options for a surrogate 
host exist, Escherichia coli has been chosen as a highly 
promising and robust cell factory for heterologous pro-
duction of NRPs and PKs, given its versatile advantages 
including easy cultivation, genetic manipulation and scal-
able fermentation [13].
Valinomycin is an NRP cyclodepsipeptide antibiotic 
that is naturally biosynthesized by several Streptomyces 
strains via the enzyme valinomycin synthetase, which 
belongs to the mRNA-independent assembly lines 
termed nonribosomal peptide synthetase (NRPS) [14–
16]. Valinomycin synthetase contains two distinct large 
NRPSs, Vlm1 (370 kDa) and Vlm2 (284 kDa), and each of 
them has two modules to assemble their dedicated sub-
strates α-ketoisovaleric acid (module 1), l-valine (mod-
ules 2 and 4) and pyruvate (module 3) (for a biosynthetic 
model see Figure 1). To realize heterologous production 
of valinomycin, we have successfully reconstituted the 
NRPS genes (vlm1 and vlm2) from Streptomyces tsusi-
maensis in an engineered E. coli host [17]. Autonomous 
formation of valinomycin could be achieved without 
substrate feeding, because the three substrates are avail-
able from the glycolysis as well as from the branched 
chain amino acid l-valine biosynthesis pathway in E. 
coli (Figure  1). The initial valinomycin titer was modest 
(0.3 mg L−1) in batch cultivations, while the titer was sig-
nificantly enhanced up to 10 mg L−1 through flask scale 
high cell density fed-batch cultivations [18]. In addition, 
coexpression of the cognate type II thioesterase (TEII), 
which is encoded in the valinomycin gene cluster and 
responsible for regeneration of the NRPS activity, with 
Vlm1 and Vlm2 further improved valinomycin produc-
tion to a final titer of 13 mg L−1 [19].
Although heterologous production of some NRPs and 
PKs in E. coli has been achieved over the last decade, only 
a few of them have been produced in large-scale bioreac-
tors, yet the yields were mostly not satisfactory [13]. The 
polyketide 6-deoxyerythronolide B (6-dEB, precursor of 
the antibiotic erythromycin) was intensively investigated 
as a model system. Up to now, the reported highest titer 
of 6-dEB was 1.1 g L−1, achieving through a 12-day high 
cell density fed-batch bioreactor fermentation [20]. How-
ever, the final compound erythromycin A just reached 
a titer of 4 mg L−1 in the bioreactor with a batch mode 
cultivation for 6  days [21]. The antitumor compound 
echinomycin was the first NRP that was heterologously 
produced in E. coli with a titer of 0.3 mg L−1 after 8 days 
of fed-batch fermentation [22]. All studies show that, 
for increased yields of the target NRPs or PKs, it is chal-
lenging not only to recombinantly express the large bio-
synthetic enzymes, but also to maintain the fitness of 
the cells over comparably long times of cultivation to 
guarantee the continuous production of the substrate 
metabolites. Therefore, more efforts, especially in the 
context of fed-batch and scale-up bioprocess develop-
ment, need to be done.
Generally, prior to scale up a bioprocess, the param-
eters are initially optimized through small scale batch 
cultivations. However, the optimized parameters might 
not be transferable directly from small batch to large 
fed-batch fermentations because of the different culti-
vation modes. Recently, the enzyme-controlled glucose 
delivery EnBase® strategy has been developed to cultivate 
microbial cells under a fed-batch type of cultivation in 
small-scale vessels such as shake flasks [23]. The EnBase 
technology enables scalability from microwell plates to 
larger bioreactors with consistent conditions for the pro-
duction of different recombinant proteins [24, 25]. While 
consistent cultivations can be solved by the EnBase sys-
tem, inhomogeneity is another main concern during the 
industrial scale fermentations due to the limited mass 
transfer. An important feature of different product yields 
in laboratory and industrial scale is especially the exist-
ence of a feeding zone which is characterized by a high 
glucose concentration [26]. As a high glucose concentra-
tion is connected to a high metabolic activity, also oxy-
gen limitation appears in such a zone at the typical high 
cell concentrations [27]. In the case of production of 
small molecules such a feeding zone directly affects the 
flux through the central metabolic pathways [28] and 
thus may influence the yield of the product. To address 
this problem, a laboratory scale-down two-compartment 
reactor (TCR) was applied to simulate the effect of the 
feed zone and thus to study the robustness of the pro-
cess [29]. The metabolic and physiological responses of 
microbial cells in the TCR cultivation environment could 
thus reflect the situations under a very similar industrial 
production process, generating useful and valuable infor-
mation for bioprocess development.
In this work, we aim to develop a rational scale-up bio-
process route at the example of valinomycin production 
(see Figure 2 for the scale-up scheme from 1 mL to 10 L), 
which we believe provides a reasonable bioprocess devel-
opment approach for realizing natural product produc-
tion to meet the demand.
Methods
Bacterial strains and culture medium
The host E. coli strain BJJ01 [F− ompT hsdS(rB− mB−) dcm+ 
TetR gal endA Hte ΔxylA::sfpwt] is a derivative of E. coli 
BL21 Gold (Agilent Technologies, Waldbronn, Ger-
many) [17]. It contains sfp gene from Bacillus subtilis for 
posttranslational phosphopantetheinylation of NRPSs 
chromosomally integrated into the xylA locus. Two valin-
omycin producing strains, E. coli BJJ01 pCTUT7-Vlm1 
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Valinomycin Valinomycin biosynthetic assembly line
Figure 1 Proposed valinomycin biosynthetic pathway in the host E. coli. Pyr pyruvate, l-Lac lactate, α-Kiv α-ketoisovalerate, d-Hiv d-hydroxyisovaler-
ate, l-Val l-valine, d-Val d-valine, ilvBN acetohydroxy acid synthase I, ilvC acetohydroxy acid isomeroreductase, ilvD dihydroxy acid dehydratase, ilvE 
branched chain amino acid aminotransferase, A adenylation domain, T thiolation domain, C condensation domain, KR ketoreductase domain, E 
epimerase domain, TE thioesterase domain. A domains select and activate the substrates. T domains are responsible for the translocation of the 
bound aminoacyl or peptidyl intermediate between adjacent catalytic positions. C domains catalyze the formation of peptide bond and elongate 
the peptide chain. The KR domain in module 1 reduces α-Kiv to d-Hiv. The E domain in module 2 transfers l-Val to d-Val. The KR domain in module 3 
reduces Pyr to l-Lac. The four modules of valinomycin synthetase are iteratively reused to assemble three tetradepsipeptide monomers, which are 
eventually oligomerized and macrolactonized to form the cyclododecadepsipeptide valinomycin.
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pKS01-Vlm2 that expresses valinomycin synthetase Vlm1 
and Vlm2 [17] and E. coli BJJ01 pJL03-Vlm1 pJL07-Vlm2 
pJL10-TEII that expresses Vlm1, Vlm2 and a third repair-
ing enzyme type II thioesterase [19], were used in this 
study. EnPresso B defined medium without any complex 
nutrients (BioSilta, Cambridge, UK) was used for valino-
mycin production in 24-well plates and shake flasks, and 
as a starter medium in the large bioreactors. The mono-
mer glucose is gradually released from the glucose pol-
ymer by a biocatalyst (Reagent A, BioSilta) to feed cells 
during the cultivation.
Cultivation in 24‑well plates
To prepare a preculture, E. coli cells were inoculated 
into 100  mL EnPresso B defined medium in 500  mL 
Ultra Yield Flasks™ (Thomson Instrument Company, CA, 
USA), which was supplemented with 0.3 U L−1 glucose-
releasing biocatalyst, 10  μL antifoam 204 (Sigma) and 
appropriate antibiotics (17 mg L−1 chloramphenicol and 
50  mg  L−1 ampicillin). The flask was incubated over-
night on an orbital shaker (amplitude: 25 mm, Infors HT, 
Switzerland) at 200 rpm and 30°C. Afterwards, the over-
night preculture was distributed without diluting it into 
the 24-well plates (PreSens Precision Sensing GmbH, 
Regensburg, Germany) with 1 mL per well. To screen the 
optimal biocatalyst concentration, additionally to the ini-
tial 0.3 U L−1 further amounts of biocatalyst were added 
to each well (1.5, 3, 9 or 15  U  L−1). The 24-well plates 
were covered with the Duetz System sandwich cover 
and clamp system (Enzyscreen, Er Haarlem, The Nether-
lands) for efficient oxygen transfer and low evaporation 
(appr. 0.1 mL per well over the cultivation time). The sub-
sequent cultivation was continued for 48  h at 30°C and 
250  rpm in a shaker (amplitude: 50  mm, Kühner, Birs-
felden, Switzerland) with online measurement of DO and 
pH (SensorDish Reader, PreSens).
Shake flask cultivation
Shake flask cultivations were performed in 500 mL Ultra 
Yield Flasks with membrane seals (both from Thomson 
Instrument Company, CA, USA) containing 100  mL 
EnPresso B defined medium with inoculation of OD600 at 
0.1. A biocatalyst concentration of 3 U L−1 to release glu-
cose was added at the start of the experiments. The culti-
vations were carried out at 200 rpm and 30°C for 12 h in 
a shaker (amplitude: 25 mm, Infors HT, Switzerland).
Bioreactor fed‑batch fermentation
The high cell density fed-batch fermentation for valino-
mycin production was performed in a 3.7  L bench-top 
bioreactor (KLF2000, Bioengineering, Switzerland). The 
cultivation comprised two phases: (1) initial cultivation 
in EnPresso B defined medium and (2) a fed-batch culti-
vation with external glucose feeding (a concentrated feed 
solution contained 400 g L−1 glucose). 2 L EnPresso B as 
a starter medium were prepared without complex nutri-
ent additives and autoclaved in the bioreactor at 121°C 
for 20  min. 3  U  L−1 biocatalyst (Reagent A, BioSilta) 
were added to the medium directly before inoculation 
with an initial OD600 of 0.1. Cells were grown at 30°C 
and the pH was maintained at 7.0 with 25% NH4OH and 














Figure 2 Scale-up bioprocess development for valinomycin production in E. coli from 1 mL to 10 L. a A representative well from the 24-well plates, 
which are incorporated with sensors allowing online measurement of oxygen and pH. Cultivations were performed in 24-well plates with 1 mL 
working volume per well (total volume 3.3 mL); b cultivations were performed in 500 mL shake flasks with 100 mL working volume; c cultivation 
was performed in a 3.7 L bioreactor with 2 L working volume; d cultivations were performed in a 15 L scale-down TCR with 10 L working volume. 
STR stirred tank reactor, PFR plug flow reactor.
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(air saturation) through adjustment of the stirrer rate 
and air flow rate during the fermentation. Foaming was 
controlled by adding 2 mL antifoam (PPG2000) per time 
manually when foam appeared.
When the glucose releasing polymer in the EnPresso B 
medium was depleted 16–18 h after inoculation (as indi-
cated by zero residual glucose), external glucose feeding 
was initiated at a rate of 0.07 mL min−1, which is calcu-
lated according to the following equation:
where X0 and V0 are the cell dry weight (g L−1) and cul-
ture volume (L) at the time of feeding start, μ is the spe-
cific growth rate (0.2 h−1), Sf is the glucose concentration 
in the feeding solution (400 g L−1), and YX/S is the yield 
coefficient (0.4 g g−1, biomass produced per glucose).
The subsequent exponential feeding process was con-
tinued for 12 h with a specific growth rate (μ) of 0.2 h−1 
and the feeding profile was calculated according to the 
following equation:
where F0 is the initial feeding rate (L h−1), µ is the specific 
growth rate (h−1) to be maintained, and t is the time (h) 
after feeding start.
Afterwards, the glucose feeding rate was gradually 
decreased from 0.85 to 0.45  mL  min−1 in 6  h to pre-
vent the DO to drop under 20% in the bioreactor, fol-
lowed by constant feeding at 0.45  mL  min−1 until the 
end of the fermentation. During the whole fed-batch 
phase, when OD600 increased by ~20, a mixture of 2 mL 
MgSO4 (1.5 M), 2 mL trace element solution [per L: 0.5 g 
CaCl2∙2H2O, 0.18  g ZnSO4∙7H2O, 0.10  g MnSO4∙H2O, 
20.1  g Na2-EDTA, 16.70  g FeCl3∙6H2O, 0.16  g 
CuSO4∙5H2O, 0.18 g CoCl2∙6H2O, 0.132 g Na2SeO3∙5H2O, 
0.12 g Na2MoO4∙2H2O, and 0.725 g Ni(NO3)2∙6H2O], and 
2  mL thiamine (50  g  L−1) was added aseptically to the 
bioreactor containing 2  L culture. Samples were drawn 
from the bioreactor for OD600 measurement, residual 
glucose determination and valinomycin quantification.
Two‑compartment reactor fermentation
To investigate valinomycin production under oscil-
lating conditions, a scale-down TCR system, which 
consists of a 15  L standard STR (B. Braun  +  Diessel 
Biotech GmbH, Germany) and a 1.2  L PFR equipped 
with static mixers, was used for the fermentation 
(see Figure  2d). The strain E. coli BJJ01 pJL03-Vlm1 
pJL07-Vlm2 pJL10-TEII was used in this experiment. 
For comparison, one reference fermentation was per-
formed in the STR without PFR. In the reference 
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medium were used for the initial cultivation followed 
by a glucose fed-batch cultivation. The exponential 
feeding was continued for 8  h with a specific growth 
rate (μ) of 0.2 h−1. In the TCR (STR + PFR) fed-batch 
fermentation, glucose was fed at the inlet of the PFR 
with the μ of 0.22 h−1 for 8 h. The culture was circu-
lated between the STR and the PFR by a pump with a 
residence time of 1  min in the PFR. The inoculation, 
cultivation temperature, DO, pH and other salt addi-
tives were kept the same as described above in “Biore-
actor fed-batch fermentation”. All samples were drawn 
from the STR for OD600 measurement, residual glucose 
determination and valinomycin quantification.
Cell growth determination
Cell growth in shake flasks and bioreactors was measured 
by optical density at 600 nm (OD600) with a UV/Vis spec-
trophotometer (Ultrospec 3300, Amersham Biosciences, 
Germany). For the 24-well plate samples, cell densities 
were automatically measured using a robotic platform 
(Hamilton Robotics, Switzerland) by mixing 5 μL culture 
with 145  μL of 0.9% NaCl in 96-microwell plates, fol-
lowed by OD600 reading with a Synergy Mx microplate 
reader (BioTek Instruments, USA). All OD600 values were 
then recalculated for a light path length of 1 cm accord-
ing to a calibration curve. All measurements were deter-
mined in triplicate.
The specific growth rate (μ) was calculated for the 
period between two consecutive OD600 measurements 
and was then fitted with the best spline.
Glucose determination
Samples were drawn from bioreactor cultivations and 
centrifuged at 12,000×g for 5 min. Residual glucose con-
centration in the supernatant was determined by the 
Glucose Hexokinase FS kit (DiaSys Diagnostic Systems 
GmbH, Holzheim, Germany).
Valinomycin preparation and analysis
Valinomycin extraction and quantification were carried 
out as previously described [18]. Briefly, 1  mL of cul-
ture was centrifuged at 16,000×g for 3  min. The result-
ing supernatant and cell pellet were extracted each with 
2  mL ethyl acetate and 2  mL methanol, respectively. 
Then the two extracts were combined, vacuum dried, and 
resuspended in 1  mL of methanol. Valinomycin analy-
sis was performed with an Agilent 6460 Triple Quadru-
pole LC/MS System using an Eclipse Plus C18 column 
(RRHD 1.8 μm, 2.1 × 50 mm) by injection of 1 μL sam-
ple volume. Separations were achieved at a flow rate of 
0.3 mL min−1 with elution buffers A (water + 0.1% for-
mic acid) and B (acetonitrile + 0.1% formic acid) through 
a linear gradient from 5 to 100% B over 2.5  min, an 
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isocratic wash at 100% B for 7.5 min and a linear decrease 
to 5% B within 2 min. Valinomycin concentrations were 
calculated according to a calibration curve generated 
with valinomycin standard (Sigma). All measurements 
were performed in triplicate.
Results and discussion
Cultivations in milliliter scale
Bioprocess development usually starts from small-scale 
cultivations to evaluate optimal parameters. However, 
those parameters may not be directly applied to the fol-
lowing large-scale production due to the inconsistent 
conditions between small and large cultivation modes 
(e.g. batch vs fed-batch). To circumvent this inconsist-
ency, we used the fed-batch type of cultivation for valino-
mycin production over the whole process development 
procedure, which is also necessary to guarantee the 
long-term production of valinomycin. While in our ear-
lier papers [18, 19], we applied media with complex addi-
tives for the production of valinomycin, here we aimed 
for simple glucose mineral salt based medium, for easier 
process development. As the building blocks for valino-
mycin all derive from the central carbon metabolism, a 
fermentation strategy based on glucose as the sole carbon 
and energy source should work out for the production of 
this NRP. An important parameter in the initial screening 
experiments was the variation of glucose feed rate, which 
was established by varying the biocatalyst concentrations 
ranging from 1.5 to 15 U L−1.
Clearly, with more biocatalyst in the culture, a lower 
dissolved oxygen (DO) level was observed during the 
first 12 h cultivation (Figure 3a). This is because glucose 
was released fast with high concentrations of biocatalyst, 
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Figure 3 Valinomycin production with different biocatalyst concentrations using EnPresso B defined medium in milliliter-scale cultivations of E. 
coli BJJ01 pCTUT7-Vlm1 pKS01-Vlm2. a Dissolved oxygen (DO) and b pH were measured online; c cell growth curves; d valinomycin production. 
An overnight preculture of E. coli BJJ01 pCTUT7-Vlm1 pKS01-Vlm2 (OD600 of ~6.0) was distributed without diluting it into the 24-well plates with 
1 mL per well (total volume 3.3 mL). Different amounts of biocatalyst (1.5, 3, 9 or 15 U L−1) were added to each well followed by 48 h cultivation at 
250 rpm and 30°C with online measurement of DO and pH.
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oxygen. After 12 h, oxygen contents from the four con-
ditions became similar and gradually increased to the 
end of the cultivation. The DO increase is likely due to 
the steadily decreasing amount of the glucose polymer, 
which also causes the growth rates of the cultures to 
decline. As shown in Figure  3b, increasing amounts of 
biocatalyst (9 and 15  U  L−1) led to a faster decrease of 
pH, suggesting possible overfeeding and accumulation 
of typical acidic products of the mixed acid fermentation 
in the first 12 h of cultivation. By contrast, at the lowest 
concentration of biocatalyst (1.5  U  L−1), the pH values 
were always the highest, indicating that cells suffered a 
higher degree of starvation from a slower glucose feed-
ing rate. With the biocatalyst concentration of 3 U L−1, 
the pH values were relatively stable at around 7.1 during 
the entire cultivation, which means that cells could grow 
continuously without overfeeding or starvation, respec-
tively, based on a balance of glucose release and con-
sumption. The changes of cell densities were reflected 
very well by the oxygen profile (Figure 3c). For example, 
with more biocatalyst cell densities were always higher 
and oxygen contents were always lower in the first 12 h 
of cultivation. Finally, all cell densities reached high 
OD600 values of ~20, although without addition of com-
plex nutrient additives which were used in our previ-
ous studies [18]. With a biocatalyst concentration of 
3 U L−1, valinomycin reached the highest titer of nearly 
800 μg L−1 and the corresponding yield was the second 
highest of 63 μg g−1 biomass (Figure 3d). In addition, the 
pH values remained stable at ~7.1 under this condition, 
which is more close to the optimal pH of 7.0 for E. coli 
growth. Therefore, 3 U L−1 of biocatalyst was applied to 
our following scale-up bioprocess development.
Shake flask cultivation
Before moving forward to bioreactor cultivations, we 
aimed to figure out the correlations between the spe-
cific growth rate of the culture and the rate of valino-
mycin formation, which could likely be referred for the 
bioreactor feeding strategy. To this end, we conducted 
cultivations in shake flasks using EnPresso B defined 
medium supplemented with 3 U L−1 of biocatalyst. As 
shown in Figure 4, after an initial lag phase cells expe-
rienced an exponential growth with a maximum spe-
cific growth rate (μ) of appr. 0.55 h−1, which declined 
after 5–6 h slowly to the end of the cultivation. Since 
leaky expression plasmids were used in our system, no 
IPTG was added to induce enzyme (Vlm1 and Vlm2) 
expression. Therefore, Vlm1 and Vlm2 can be gradu-
ally expressed from the beginning of the cultivation 
to synthesize valinomycin, and after 6  h cultivation 
the valinomycin titer was determined to be around 
50  μg  L−1. Although the μ dropped below 0.2  h−1 
between 8 and 12  h, valinomycin accumulated up to 
approximately 300  μg  L−1 with the highest specific 
product formation rate (qp) of 6.87 μg  L−1  OD−1  h−1 
during this period. This could be probably explained 
that cells grow slower, but have enough time to express 
the two large enzymes for the biosynthesis of valino-
mycin. On the other hand, increasingly expressed 
enzymes and valinomycin can improve cell meta-
bolic burden and thus inhibit cell growth. The results 
indicate that the accumulation of valinomycin could 
be maintained even at a specific growth rate below 
0.2  h−1. Moreover, shake flask cultivations also gen-
erated similar valinomycin yields (65 μg g−1 biomass) 
compared to the 24-well plate cultivations (63 μg g−1 
Figure 4 Valinomycin production in shake flask scale cultivations of E. coli BJJ01 pCTUT7-Vlm1 pKS01-Vlm2. Cultivations were performed in 500 mL 
flasks containing 100 mL EnPresso B defined medium at 200 rpm and 30°C for 12 h. The glucose releasing biocatalyst concentration was 3 U L−1.
Page 8 of 13Li et al. Microb Cell Fact  (2015) 14:83 
biomass). From these experiments we concluded that 
the formation of valinomycin is relatively robust in 
relation to the specific growth rate and may even be 
higher at low growth rates.
Bioreactor high cell density fed‑batch fermentation
In order to scale up the cultures to higher cell densities, a 
cultivation was performed in a 3.7  L bench-top bioreac-


































































































































































Figure 5 Fed-batch bioreactor cultivation for valinomycin production. a Cell growth curve, specific growth rate, glucose feeding rate and residual 
glucose concentration; b valinomycin production; c profiles of online dissolved oxygen (DO), pH and stir speed.
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initial batch mode cultivation in the bioreactor, the fed-
batch-like EnPresso B was used as a starter medium for the 
high cell density cultivation, which would confer cells with 
consistent intracellular physiological conditions, avoiding 
overflow metabolism in the initial cultivation phase [24]. 
Since modest yields of valinomycin could be reached with-
out nutrient boosting (Figure 3d), the bioreactor fed-batch 
production was performed only based on pure glucose feed-
ing without addition of complex nutrient additives. The cul-
tivation in the bioreactor was started with an initial OD600 of 
0.1 and 3 U L−1 of biocatalyst was added for glucose release 
in the initial phase. During the whole fermentation, E. coli 
BJJ01 pCTUT7-Vlm1 pKS01-Vlm2, the same strain as in 
the previous small scale cultivations, was grown at 30°C 
with a constant pH of 7.0 and the DO was maintained above 
20%.
After 16–18  h of cultivation, the glucose polymer in 
the EnPresso B medium was depleted, as indicated by the 
continuous increase of DO (Figure  5c). Also the levels 
of glucose were below the detection limit in this period 
(Figure 5a). Therefore, at 19 h the external glucose feed-
ing was initiated with an exponential feed profile for a 
targeted specific growth rate (μ) of 0.2 h−1. The feeding 
was continued for 12 h followed by a gradual decrease to 
a constant feeding to the end of the fermentation (Fig-
ure 5a) to avoid the culture to run into oxygen limitation.
Initially, cells grew exponentially along with the expo-
nential feeding protocol and reached the specific growth 
rate of 0.2 h−1. When the feeding was adjusted to a con-
stant rate, the specific growth rate dropped to below 
0.05 h−1 until the end of the cultivation with a final OD600 
of approximately 120 (Figure 5a).
Valinomycin titers were measured hourly after 
starting of the glucose feeding (see Figure  5b). The 
volumetric valinomycin concentration increased during 
the exponential feed phase to a titer of about 2 mg L−1 
followed by a gradual slight decrease, which is due to 
the continuous dilution of the bioreactor by the feed 
solution. The valinomycin yield based on biomass was 
the highest of appr. 150 μg g−1 biomass until the mid of 
the exponential feed phase but declined in the second 
half of the cultivation. Unlike our previous results that 
high cell densities generated high valinomycin concen-
tration in the shake flask scale [18], a high cell density 
cultivation in the bioreactor did not further improve 
the valinomycin titers. SDS-PAGE analysis of Vlm1 and 
Vlm2 bands showed a distinct difference to all our pre-
vious cultivations, where both enzymes were expressed 
approximately with the same strength. While Vlm1 was 
expressed to a high level throughout the whole fermen-
tation, Vlm2 was not well expressed (Figure  6). The 
much lower expression of Vlm2 is probably due to the 
plasmid instability in the cells because pCTUT7-Vlm1 
and pKS01-Vlm2 have the same origin of replication. 
Interestingly enough, the expression of Vlm2 had not 
been a problem in our earlier studies at the small scale 
(see also [17, 18]). Therefore, we decided in the follow-
ing scale up study to use the strain with plasmids which 
contain different origins of replication as described in 
our recent paper [19].
Valinomycin production in a two‑compartment reactor
While the previous fed-batch bioreactor process indi-
cated that the scale up of the valinomycin process from 
shaken cultures to bioreactor scale is not easily predict-
able, we aimed to test the robustness of valinomycin 
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Figure 6 SDS-PAGE analysis of Vlm1 and Vlm2 expression during the bioreactor fermentation. Cells were collected at different time intervals from 
the bioreactor as shown on the top of the gels. Protein samples were separated on a 5% polyacrylamide gel. Vlm1 (370 kDa) and Vlm2 (284 kDa) are 
indicated by arrows. P insoluble protein, S soluble protein, M protein molecular weight marker.
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Therefore, parallel experiments were performed either 
in a stirred tank reactor (STR) or in a scale-down TCR 
(see Figure  2d). According to the results we had two 
hypotheses: (1) the high glucose levels and oxygen limi-
tation in the plug flow reactor (PFR) part of the reac-
tor together with the higher starvation effect in the 
STR compartment might decrease the valinomycin 
production; (2) while previous investigations indicated 
that pyruvate and l-valine can be significantly accumu-
lated in E. coli after a repeated short-time downshift of 
oxygen at a high glucose concentration in a bioreactor 
fed-batch fermentation [30] and also under repeated 
oscillations of these conditions in a scale down biore-
actor [31], one also might hypothesize that such a two-
compartment bioreactor cultivation could even increase 
valinomycin biosynthesis through increasing the flux 
of glucose to the synthesis of its precursors pyruvate, 
α-ketoisovalerate and l-valine. To simulate these condi-
tions, we used a 15  L scale-down TCR (see Figure  2d) 
for valinomycin production. This TCR system allows 
continuous circulation of the culture between a STR 
and a PFR, generating the oscillating fermentation con-
ditions with high glucose and oxygen limitation in the 
PFR loop with a residence time of approximately 1 min 
[26, 27].
To overcome the instability of multiple plasmids in one 
cell, we have constructed new plasmids with compat-
ible origins of replication for enzyme expression, and we 
further improved the system by coexpression of the TEII 
enzyme [19]. Figure  7 shows valinomycin production 
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Figure 7 Valinomycin production under oscillating conditions in a scale-down two-compartment reactor. a Cell growth curves, specific growth 
rate and residual glucose concentration; b valinomycin production. STR stirred tank reactor, TCR two-compartment reactor.
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with the strain E. coli BJJ01 pJL03-Vlm1 pJL07-Vlm2 
pJL10-TEII under oscillating conditions in the scale-
down TCR (STR  +  PFR) system. The fermentation in 
the STR without PFR was performed as a reference. In 
both the STR and the TCR fermentations, glucose feed-
ing was initiated at an OD600 of ~4 (Figure  7a). In the 
STR, glucose was directly fed into the bioreactor, while 
in the TCR glucose was fed at the inlet of the PFR (see 
Figure 2d), forming a high glucose and anaerobic growth 
environment. The feeding process was continued for 8 h 
and samples were drawn from the STR every hour for 
analysis. In agreement with published data, OD600 values 
in the control STR fermentation were always higher than 
those in the TCR fermentation even though the OD600 
values were similar at the starting point of glucose feed-
ing (Figure 7a). This is typical for all large scale processes 
with imperfect mixing [27]. Likewise, the volumetric 
valinomycin titers in the TCR fed-batch fermentation 
were also lower than the reference STR fermentation 
(Figure 7b). However, the specific valinomycin yields (i.e. 
g per g cell biomass) were higher in TCR than in the STR 
fermentation during the initial 6 h fed-batch cultivation 
(Figure 7b). The expression levels of Vlm1 and Vlm2 were 
analyzed by SDS-PAGE and as expected both enzymes 
were expressed equally without a significant change over 
the cultivation (Figure 8).
This first result is promising, as it indicates that valino-
mycin production is not disturbed by effects which are 
caused by non-perfect mixing and therefore the process 
should be robust for scale up. Furthermore, the higher 
yield of valinomycin on a cell basis (Figure 7b) suggests 
that there is space for further optimization by variation 
of the perturbances. Possibilities are variations in the 
strength and the intervals of the pulses. Such engineer-
ing approaches should go hand in hand with a further 
optimization of the genetic system. The biomass specific 
production yields for the strain E. coli BJJ01 pJL03-Vlm1 
pJL07-Vlm2 pJL10-TEII are only 30–50% of the produc-
tion yields in E. coli BJJ01 pCTUT7-Vlm1 pKS01-Vlm2, 
which well agrees with the higher amounts of soluble 
Vlm1 and Vlm2, respectively, in the latter strain (data 
not shown). Thus, we conclude that also the amount of 
Vlm1 and Vlm2 currently limits the accumulation rate of 
valinomycin.
Conclusions
In this work, valinomycin production was scaled up from 
mL volumes to 10 L scale with consistent fed-batch cul-
tivations, which illustrates a blueprint of rational bio-
process development for other complex natural product 
production. Based on the fed-batch-like EnBase culti-
vation system, the process development procedure for 
valinomycin production from small to larger scale was 
efficient by the ability to perform simple-to-perform 
parallel cultivations. The bioreactor high cell density fed-
batch fermentation produced valinomycin with titers 
of more than 2 mg L−1 based on a pure glucose feeding 
strategy. Valinomycin production was not negatively 
affected by the oscillating conditions (i.e. glucose sup-
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Figure 8 SDS-PAGE analysis of Vlm1 and Vlm2 expression during the two-compartment bioreactor fermentation. a Vlm1 and Vlm2 expression in 
the STR; b Vlm1 and Vlm2 expression in the TCR. Cells were collected at different time intervals as shown on the top of the gels. Protein samples 
were separated on a 5% polyacrylamide gel. Vlm1 (370 kDa) and Vlm2 (284 kDa) are indicated by arrows. P insoluble protein, S soluble protein, M 
protein molecular weight marker.
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situations in industrial bioreactors, indicating that a scal-
ing of the bioprocess to large industrial scale should be 
achievable.
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